文献速递免疫规划妇幼与学校卫生

坦桑尼亚9-14岁女孩单剂HPV疫苗(DoRIS)与肯尼亚15-20岁年轻女性单剂接种(KEN SHE)的免疫桥接分析:随机对照试验

Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials.
PubMed 文献 · Lancet Glob Health · 2024-01-01

研究比较坦桑尼亚9-14岁女孩(DoRIS试验,930人随机分配至2价或9价HPV疫苗1、2、3剂)与肯尼亚15-20岁女性(KEN SHE试验,单剂同种疫苗)接种后24个月HPV16/18抗体应答。结果显示两组抗体几何平均浓度相似或更高,非劣效性成立,提示目标年龄女孩单剂接种可诱导与有效人群相当的免疫应答。

要点

  • DoRIS试验中9-14岁女孩单剂2价或9价HPV疫苗后24个月HPV16/18抗体GMC与KEN SHE中15-20岁单剂女性相似或更高。
  • 2价疫苗GMC比值(DoRIS:KEN SHE)HPV16为0.90(95%CI 0.72-1.14),HPV18为1.02(0.78-1.33)。
  • 9价疫苗GMC比值HPV16为1.44(95%CI 1.14-1.82),HPV18为1.47(1.13-1.90),非劣效性均成立。

核心结论

  • 目标年龄女孩单剂HPV疫苗后24个月免疫应答与已显示效力的单剂年轻女性相当,可能对持续性HPV16/18感染有效至少两年。

研究设计与样本

  • 免疫桥接分析,比较DoRIS随机对照试验(坦桑尼亚930名9-14岁女孩随机接受1、2或3剂2价Cervarix或9价Gardasil-9)与KEN SHE随机对照试验(肯尼亚15-20岁女性随机接受单剂同种疫苗)。
  • 采用病毒样颗粒ELISA法批检样本检测HPV16和HPV18 IgG抗体。
  • 非劣效性预先定义为GMC比值(DoRIS:KEN SHE)95%CI下限小于0.50。

主要发现

  • 第24个月DoRIS中HPV16和HPV18抗体GMC与KEN SHE相似或更高。
  • 2价疫苗GMC比值:HPV16为0.90(95%CI 0.72-1.14),HPV18为1.02(95%CI 0.78-1.33)。
  • 9价疫苗GMC比值:HPV16为1.44(95%CI 1.14-1.82),HPV18为1.47(95%CI 1.13-1.90)。
  • 两种疫苗对HPV16和HPV18的抗体GMC和血清阳性率的非劣效性均成立。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first randomised controlled trial of single-dose human papillomavirus (HPV) vaccine efficacy, the Kenya single-dose HPV-vaccine efficacy (KEN SHE) trial, showed greater than 97% efficacy against persistent HPV16 and HPV18 infection at 36 months among women in Kenya. We compared antibody responses after one dose of HPV vaccine in the Dose Reduction Immunobridging and Safety Study (DoRIS), the first randomised trial of the single- dose regimen in girls aged 9-14 years, the target age range for vaccination, with those after one dose of the same vaccine in KEN SHE. METHODS: In the DoRIS trial, 930 girls aged 9-14 years in Tanzania were randomly assigned to one, two, or three doses of the 2-valent vaccine (Cervarix) or the 9-valent vaccine (Gardasil-9). The proportion seroconverting and geometric mean concentrations (GMCs) at month 24 after one dose were compared with those in women aged 15-20 years who were randomly assigned to one dose of the same vaccines at the same timepoint in KEN SHE. Batched samples were tested together by virus-like particle ELISA for HPV16 and HPV18 IgG antibodies. Non-inferiority of GMC ratios (DoRIS trial:KEN SHE) was predefined as a lower bound of the 95% CI less than 0·50. FINDINGS: Month 24 HPV16 and HPV18 antibody GMCs in DoRIS were similar or higher than those in KEN SHE. 2-valent GMC ratios were 0·90 (95% CI 0·72-1·14) for HPV16 and 1·02 (0·78-1·33) for HPV18. 9-valent GMC ratios were 1·44 (95% CI 1·14-1·82) and 1·47 (1·13-1·90), respectively. Non-inferiority of antibody GMCs and seropositivity was met for HPV16 and HPV18 for both vaccines. INTERPRETATION: HPV16 and HPV18 immune responses in young girls 24 months after a single dose of 2-valent or 9-valent HPV vaccine were comparable to those in young women who were randomly assigned to a single dose of the same vaccines and in whom efficacy had been shown. A single dose of HPV vaccine, when given to girls in the target age range for vaccination, induces immune responses that could be effective against persistent HPV16 and HPV18 infection at least two years after vaccination. FUNDING: The UK Department of Health and Social Care, the Foreign, Commonwealth, & Development Office, the Global Challenges Research Fund, the UK Medical Research Council and Wellcome Trust Joint Global Health Trials scheme, the Bill and Melinda Gates Foundation, the US National Cancer Institute; the US National Institutes of Health, and the Francis and Dorothea Reed Endowed Chair in Infectious Diseases. TRANSLATION: For the KiSwahili translation of the abstract see Supplementary Materials section.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Baisley K, Kemp TJ, Mugo NR, et al. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials. Lancet Glob Health. 2024. PMID: 38365419. doi:10.1016/S2214-109X(23)00586-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。